Wissenschaftliche Arbeiten

Uzm. Dr. Duygu Ercan Uzundal

13 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Re: Three versus Six Cycles of Platinum-Based Chemotherapy Followed by Avelumab Maintenance as First-Line Treatment for Advanced Urothelial Cancer: The Phase II DISCUS Trial

    European Urology, 2026

    DOI 10.1016/j.eururo.2026.03.010 PMID 41925429 Quelle: OpenAlex

  3. Lenvatinib Dose Intensity and Tumor Response in Renal Cell Carcinoma Considering Tumor Burden and Nephrectomy Timing

    2026

    DOI 10.1093/jjco/hyag195 Quelle: ORCID

  4. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

    Turkish Journal of Gastroenterology, 2025

    DOI 10.5152/tjg.2025.24784 PMID 40241388 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  5. Investigation of systemic treatment responses and prognostic factors in metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)

    Journal of Health Sciences and Medicine, 2025

    DOI 10.32322/jhsm.1744286 Frei zugänglicher VolltextQuelle: ORCID

  6. 2914eP Association between quality of life and sleep disturbances, anxiety, depression, and fatigue during and after (neo)adjuvant taxane-based chemotherapy in breast cancer patients

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3526 Frei zugänglicher VolltextQuelle: OpenAlex

  7. Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study

    Current Oncology, 2024

    DOI 10.3390/curroncol31110502 PMID 39590133 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  8. 1492P The role of LACE index in predicting 30-day unplanned readmission in patients receiving immunotherapy

    Annals of Oncology, 2024

    DOI 10.1016/j.annonc.2024.08.1557 Frei zugänglicher VolltextQuelle: ORCID

  9. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving Chemoimmunotherapy

    Expert Opinion on Pharmacotherapy, 2024

    DOI 10.1080/14656566.2024.2391007 PMID 39115275 4 Zitationen (Europe PMC) Quelle: ORCID

  10. Quality and Reliability Analysis of Videos About Thulium Laser Enucleation of the Prostate on Youtube

    Urology, 2024

    DOI 10.1016/j.urology.2024.07.008 PMID 39002845 1 Zitation (Europe PMC) Quelle: ORCID

  11. 1603P The ability of the LACE index to predict 30-day readmissions in oncology patients

    Annals of Oncology, 2023

    DOI 10.1016/j.annonc.2023.09.800 Frei zugänglicher VolltextQuelle: ORCID

  12. 2152P Prognostic importance of GRIM score on sorafenib side effects, hospitalization and survival in hepatocellular cancer patients

    Annals of Oncology, 2023

    DOI 10.1016/j.annonc.2023.09.934 Frei zugänglicher VolltextQuelle: ORCID

  13. Multidisciplinary Approach in Lemierre’s Syndrome: A Case Report

    Klimik Dergisi/Klimik Journal, 2020

    DOI 10.5152/kd.2020.21 Frei zugänglicher VolltextQuelle: OpenAlex